Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 0.69 |
| ▸ | DRD3 | P35462 | 2/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | ME2 | P23368 | 2/20 | 0.59 |
| ▸ | ME1 | P48163 | 2/20 | 0.59 |
| ▸ | ME3 | Q16798 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11208238 | 0.98 | DRD4 (0.97) | DRD4DRD2DRD3SIGMAR1HTR2C | |
| SCHEMBL9720693 | 0.93 | DRD4 (0.87) | DRD4DRD2DRD3SIGMAR1HTR7 | |
| SCHEMBL6031812 | 0.87 | DRD4 (1.00) | DRD4DRD2DRD3SIGMAR1HTR7 | |
| SCHEMBL9720752 | 0.87 | DRD4 (0.77) | DRD4DRD2DRD3SIGMAR1GAA | |
| SCHEMBL5542234 | 0.85 | DRD4 (0.73) | DRD4DRD2DRD3SIGMAR1HTR2C | |
| SCHEMBL3320211 | 0.85 | DRD4 (0.74) | DRD4DRD2DRD3SIGMAR1HTR2C | |
| SCHEMBL9720819 | 0.85 | DRD4 (0.73) | DRD4DRD2DRD3SIGMAR1HTR2C | |
| SCHEMBL27903298 | 0.85 | DRD4 (0.73) | DRD4DRD2DRD3HTR2CME2 | |
| SCHEMBL5540754 | 0.85 | DRD4 (0.73) | DRD4DRD2DRD3SIGMAR1HTR2C | |
| SCHEMBL588149 | 0.84 | DRD4 (1.00) | DRD4DRD2DRD3SIGMAR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7750012-B2 | Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2010-07-06 | — | — | US | disclosed |
| US-7750012-B2 | Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2010-07-06 | — | — | US | disclosed |
| US-7750012-B2 | Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2010-07-06 | — | — | US | disclosed |
| EP-1968961-A2 | BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | Decode Genetics EHF (IS) | 2008-09-17 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| WO-2007078335-A2 | BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF. (IS) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007078335-A2 | BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF. (IS) | 2007-07-12 | — | — | WO | disclosed |
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTC4S, LTB4R | DRD4 3195/4885DRD2 4311/4885DRD3 3745/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | DRD4 368/4885DRD2 542/4885DRD3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.